Role of glycosyltransferase PomGnT1 in glioblastoma progression
Open Access
- 1 August 2014
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (2), 211-222
- https://doi.org/10.1093/neuonc/nou151
Abstract
Glioblastoma multiforme (GBM) is the most aggressive and invasive brain tumor, for which novel prognostic markers and predictors of therapeutic response are urgently needed. We reported previously that levels of peptide-O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1 (PomGnT1) in glioma specimens correlated with tumor grade. However, the prognostic significance of PomGnT1 in glioma patients and its function in GBM progression remain unknown. Clinical relevance of PomGnT1 in GBM patients' prognosis was analyzed both in a clinically annotated expression dataset of 446 GBM tumor specimens and in 82 GBM tumor samples collected at our institution. The function of PomGnT1 in glioma growth and invasion, and the underlying mechanisms of PomGnT1 regulation were explored in vitro and in vivo. PomGnT1 expression in GBM tissues was closely associated with poor prognosis in GBM patients. Forced overexpression of PomGnT1 in glioblastoma cells impaired cell adhesion and increased their proliferation and invasion in vitro. Subsequent in vivo experiments showed that overexpression of PomGnT1 promoted tumor growth and shortened the survival time of tumor-bearing mice in an orthotopic model. Conversely, stable short hairpin RNA–mediated knockdown of PomGnT1 expression produced opposite effects both in vitro and in vivo. Mechanistic studies revealed that activation of epidermal growth factor receptor (EGFR) resulted in EGFR/extracellular signal-regulated kinase–dependent upregulation of PomGnT1, downregulation of receptor-type protein tyrosine phosphatase β, and activation of β-catenin pathway signaling. These findings suggest that PomGnT1 promotes GBM progression via activation of β-catenin and may serve as a prognostic factor for glioma patient survival as well as a novel molecular target for anticancer therapy in malignant glioma.This publication has 36 references indexed in Scilit:
- EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in GlioblastomaCancer Cell, 2013
- Emerging Biomarkers in GlioblastomaCancers, 2013
- High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistanceNeuro-Oncology, 2013
- Genetics of adult gliomaCancer Genetics, 2012
- Down-regulation of the Epidermal Growth Factor Receptor by Altering N-Glycosylation: Emerging Role of beta 1,4-Galactosyltransferases2012
- SHP-1 inhibits β-catenin function by inducing its degradation and interfering with its association with TATA-binding proteinCellular Signalling, 2011
- The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cellsCancer Cell, 2005
- O-Mannosyl glycans in mammalsBiochimica et Biophysica Acta (BBA) - General Subjects, 1999
- An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophyNature, 1998
- Relationship between gene amplification and chromosomal deviations in malignant human gliomasCancer Genetics and Cytogenetics, 1987